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For PD-L1-Positive Squamous Cell Carcinoma of the Anal Canal: Preliminary Safety and Efficacy Results From KEYNOTE-028.
Background: Safety and efficacy of pembrolizumab, a humanized programmed death 1 monoclonal antibody, was assessed
in KEYNOTE-028, a multicohort, phase Ib trial for patients with programmed death ligand 1 (PD-L1)-positive advanced solid
tumors. We report results for the cohort of patients with advanced anal carcinoma.
Patients and methods: Patients with PD-L1-positive tumors (1%) received intravenous pembrolizumab 10mg/kg once
every 2 weeks for up to 2 years or until confirmed progression or unacceptable toxicity. Response was assessed every 8 weeks
for the first 6 months and every 12 weeks thereafter per Response Evaluation Criteria In Solid Tumors, version 1.1. Primary end-
points were safety and overall response rate per investigator review. Secondary endpoints included progression-free survival,
overall survival, and response duration. Data cutoff date was 1 July 2015.
Results: Of the 43 patients with advanced anal carcinoma evaluable for PD-L1 expression, 32 (74%) had PD-L1-positive tumors
as assessed with the 22C3 prototype assay, of whom 25 were enrolled between April and September 2014. Sixteen patients
(64%) experienced treatment-related adverse events; the most common ones were diarrhea and fatigue in four patients (16%)
each and nausea in three patients (12%). There were no treatment-related deaths or discontinuations as of the data cutoff
date. Among the 24 patients with squamous cell carcinoma histology, four had confirmed partial response, for an overall re-
sponse rate of 17% [95% confidence interval (CI), 5%–37%) and 10 (42%) had confirmed stable disease, for a disease control
rate of 58%. One additional patient with non-squamous histology had confirmed stable disease.
Conclusion: In this population of patients with PD-L1-positive advanced squamous cell anal carcinoma, pembrolizumab dem-
onstrated a manageable safety profile and encouraging antitumor activity. These data support further study of pembrolizumab
for this patient population.
ClinicalTrials.gov: NCT02054806.
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Introduction
Anal carcinoma is a rare cancer type, with an incidence of 1–2 cases/
100 000 per year worldwide [1]. Approximately 84% of anal carcin-
oma is associated with high-risk types of human papilloma virus
(HPV), primarily HPV-16 [2]. The standard of care for localized
disease is chemotherapy with 5-fluorouracil (5-FU) and mitomycin
in combination with radiotherapy, which results in a 5-year
disease-free survival rate of 60% [3–5]. Based on limited data,
the standard of care after progression or development of
distant metastatic disease is 5-FU and cisplatin, and the 5-year
survival rate for these patients is15%; however, if cisplatin-based
chemotherapy fails, no other regimens have been shown to be
effective [6].
Many cancers evade immune surveillance and destruction
through upregulation of the immune cell checkpoint molecule
programmed death ligand 1 (PD-L1). Interaction between the
programmed death 1 (PD-1) receptor, expressed on tumor-infil-
trating T cells, and its ligand PD-L1 leads to the functional inacti-
vation of T cells, a mechanism known as adaptive immune
resistance [7, 8]. Monoclonal antibodies against PD-1 and PD-
L1, including pembrolizumab, nivolumab, and atezolizumab,
have demonstrated antitumor activity in a diverse set of tumor
types [9–11]. A correlation between pretreatment PD-L1 expres-
sion and response to anti-PD-1 therapy has also been reported in
multiple tumor types [12–14].
The KEYNOTE-028 study evaluated pembrolizumab mono-
therapy in 20 different PD-L1-positive advanced or recurrent
cancers with significant unmet medical need. Results from the
anal carcinoma cohort of KEYNOTE-028 are reported herein.
Methods
Study design and population
KEYNOTE-028 (ClinicalTrials.gov, NCT02054806) is a multicenter,
open-label, phase Ib trial in 20 cohorts of patients with PD-L1-positive
advanced solid tumors. Patients in the anal carcinoma cohort were en-
rolled at 12 investigational sites in Europe and the USA.
Eligible patients had histologically or cytologically confirmed locally
advanced or metastatic carcinoma of the anal canal, failure of prior
standard therapy, and tumor PD-L1 positivity. Other eligibility require-
ments were age18 years, measurable disease based on Response
Evaluation Criteria In Solid Tumors, version 1.1 (RECIST v.1.1), Eastern
Cooperative Oncology Group performance status of 0 or 1, and adequate
organ function as established by laboratory testing conducted<10 days
before the first pembrolizumab dose. Key exclusion criteria included
diagnosis of immunodeficiency or systemic steroid therapy<7 days be-
fore the first pembrolizumab dose, active autoimmune disease, intersti-
tial lung disease, active brain metastases (metastases stable for4 weeks
before the first pembrolizumab dose were permitted), and previous ther-
apy with an immune checkpoint inhibitor. The study protocol and all
amendments were approved by the institutional review boards or ethics
committees of all participating sites. All patients provided written in-
formed consent.
Treatment and assessments
Pembrolizumab was given intravenously at 10 mg/kg once every 2 weeks
for up to 2 years or until confirmed disease progression, unacceptable
toxicity, or patient/investigator decision. Response was assessed by
computed tomography or magnetic resonance imaging every 8 weeks for
the first 6 months and every 12 weeks thereafter. Adverse events (AEs)
were monitored throughout the study and for 30 days after the end of
treatment (90 days for serious AEs) and graded according to the National
Cancer Institute Common Terminology Criteria for Adverse Events, ver-
sion 4.0. AEs of special interest were defined as events with potentially
drug-related immunologic causes.
An archived formalin-fixed, paraffin-embedded tumor sample or a
newly obtained biopsy specimen was assessed at a central laboratory for
PD-L1 expression at screening with a laboratory-developed prototype
immunohistochemistry (IHC) assay (QualTek Molecular Laboratories,
Goleta, CA) [15] using the 22C3 antibody (Merck & Co., Inc.,
Kenilworth, NJ). PD-L1 positivity was defined as membrane staining of
1% of scorable cells, including both neoplastic cells and contiguous
mononuclear inflammatory cells, or the presence of a distinctive interface
pattern.
Outcomes
Primary endpoints were safety and overall response rate (ORR). ORR
was determined by investigator assessment and defined as the proportion
of patients having confirmed complete response (CR) or partial response
(PR) per RECIST v1.1 at any time during the study. Secondary endpoints
included progression-free survival (PFS), defined as time from enroll-
ment to the first documented instance of disease progression according
to RECIST v1.1 or death from any cause, whichever occurred first; overall
survival (OS), defined as time from enrollment to death from any cause;
and duration of response (DOR), defined as time from the first RECIST
v1.1-based response to disease progression in patients who experienced
PR or better.
Statistical analysis
The binomial exact method was used for power and sample size calcula-
tions. A sample size of 22 assessable patients in this cohort was calculated
to provide 80% power to demonstrate that the best ORR exceeded 10%
at an overall one-sided 8% alpha-level if the true ORR within the cohort
was 35%. Efficacy was assessed in patients who received1 dose of pem-
brolizumab and had measurable disease at baseline according to RECIST
v1.1. Safety was assessed in patients who received1 dose of pembrolizu-
mab. The truncated sequential probability test was used for evaluation of
ORR. The Kaplan–Meier method was used to estimate PFS, OS, and
DOR. The data cutoff date for this report was 1 July 2015.
Results
Baseline patient characteristics
Of 43 patients screened for PD-L1 expression, 32 (74%) had PD-
L1-positive tumors as assessed with the prototype IHC assay.
Four of these patients did not meet eligibility criteria, three were
excluded after the enrollment limit was reached, and the other 25
were enrolled between April and September 2014. Median age
was 63 years (range 46–82 years), 23 patients (92%) were women,
and the majority (96%) had squamous cell carcinoma (SCC)
(Table 1). One patient with non-SCC histology (perineal epi-
dermoid carcinoma) was enrolled as a protocol violation. Most
patients were pretreated, with 13 (52%) having received2 prior
treatments for advanced disease. Although three (12%) patients
did not receive prior treatment of advanced disease, they experi-
enced disease progression shortly after receiving adjuvant and/or
(neo)adjuvant treatment.
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Safety
As of the data cutoff date, median follow-up duration was 10.6
months (range 0.3–15.0 months) and median duration of therapy
was 92 days (range 1–449 days). Sixteen patients (64%) experi-
enced treatment-related AEs (Table 2), most commonly diarrhea,
fatigue (n¼ 4 each; 16%), and nausea (n¼ 3; 12%). There were
four grade 3 treatment-related AEs, including increased blood
thyroid-stimulating hormone (TSH) level and general physical
health deterioration (n¼ 1 each), and colitis and diarrhea in the
same patient. No grade 4 or higher treatment-related AEs were
seen. Treatment-related AEs of special interest occurred in three
patients (12%): grade 2 hypothyroidism in two patients and
grade 3 colitis in one patient. One additional patient experienced
grade 2 hypothyroidism not considered by the investigator to be
related to treatment and grade 3 treatment-related increased
TSH, which was not included as a term in the analysis of AEs of
special interest.
Of 25 enrolled patients, one patient discontinued therapy be-
cause of toxicity before the first postbaseline response evaluation
(grade 5 intestinal perforation unrelated to pembrolizumab treat-
ment). There were no treatment-related study discontinuations
or deaths as of the data cutoff date.
Clinical activity
By investigator review, ORR was 17% [95% confidence interval
(CI), 5.0%–37%] among the 24 patients with SCC histology, and
all four patients had confirmed PR (Table 3). Ten patients (42%)
had confirmed stable disease (SD) with a median duration of 3.6
months (range 1.8þ to 11þmonths). The disease control rate
was 58% (14 of 24 patients). The one patient with non-SCC hist-
ology (perineal epidermoid carcinoma) had confirmed SD at
9 weeks and unconfirmed PR as of the data cutoff date and was
Table 1. Patient baseline characteristics
Characteristic N5 25
Median age, years (range) 63 (46–82)
Sex
Male 2 (8)
Female 23 (92)
Race
White 19 (76)
Black or African American 1 (4)
Not specified 5 (20)
ECOG performance status
0 5 (20)
1 20 (80)
Histology at baseline
SCC 24 (96)
Perineal epidermoid carcinomaa 1 (4)
Adjuvant or neoadjuvant systemic therapy 6 (24)
Prior radiation 18 (72)
Prior lines of therapy for advanced disease
0b 3 (12)
1 7 (28)
2 6 (24)
3 7 (28)
Unknown 2 (8)
Prior therapies for advanced diseasec
5-FU þ mitomycin 15 (60)
5-FU6 platinum6 other 12 (48)
Gemcitabine þ platinum6 other 4 (16)
Chk-1 inhibitor 2 (8)
Etirinotecan pegol 2 (8)
Other 10 (40)
Data are presented as n (%) unless indicated otherwise.
aProtocol violation.
bAlthough these three patients did not receive prior treatment for
advanced disease, they had disease progression shortly after receiving
adjuvant and/or (neo)adjuvant treatment.
cPatients could have received>1 prior therapy.
5-FU, 5-fluorouracil; Chk-1, checkpoint kinase 1; ECOG, Eastern
Cooperative Oncology Group; SCC, squamous cell carcinoma.
Table 2. Treatment-related adverse events
Any-grade adverse events occurring in2 patients, n (%) N5 25
Diarrhea 4 (16)
Fatigue 4 (16)
Nausea 3 (12)
Dry mouth 2 (8)
Hypersensitivity 2 (8)
Hypothyroidism 2 (8)
Night sweats 2 (8)
Stomatitis 2 (8)
Thrombocytopenia 2 (8)
Vomiting 2 (8)
Grade 3--4 adverse events occurring in1 patient, n (%)
Colitis (grade 3)a 1 (4)
Diarrhea (grade 3)a 1 (4)
General physical health deterioration (grade 3) 1 (4)
Increased blood thyroid stimulating hormone (grade 3) 1 (4)
aOccurred in the same patient.
Table 3. Best overall response in patients with SCC histology (N5 24)
Best responsea n % 95% CI
Complete response 0 0 0–14
Partial response 4 17 5–37
Stable disease 10 42 22–63
Progressive disease 9 38 19–59
Not assessedb 1 4 0–21
aAll responses are confirmed.
bPatient discontinued therapy because of toxicity before the first post-
baseline response assessment.
CI, confidence interval; SCC, squamous cell carcinoma.
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subsequently lost to follow-up. All five responders, regardless of
histology, had received prior therapy for advanced disease.
Overall, nine (38%) of 24 assessable patients had a decrease
from baseline in the size of their target lesions (Figure 1A), which
was maintained over several assessments (Figure 1B). Among the
five patients with a response, regardless of histology, median time
to response was 3.6 months (range 1.6–4.8 months), and median
DOR was not reached (range<0.1þ to 9.2þmonths). At the
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Figure 1. (A) Maximum change from baseline in tumor size. Includes patients with1 postbaseline tumor assessment (n¼ 24). Responders were defined as patients having confirmed
complete response or partial response per RECIST v1.1 by investigator review. (B) Longitudinal change from baseline in tumor size. Includes patients with1 postbaseline tumor assessment
(n¼ 24). Responders were defined as patients having confirmed complete response or partial response per RECIST v1.1 by investigator review. (C) Treatment exposure and response duration.
The length of each bar represents the time to the last radiographic assessment. Both confirmed and unconfirmed responses per RECIST v1.1 by investigator review are shown.
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time of analysis, two of the four responses in patients with SCC
histology were ongoing (Figure 1C) and were sustained for longer
than 9 months (see supplementary materials, available at Annals
of Oncology online, for additional details on these two patients).
Two patients with SD also remained on treatment as of the data
cutoff date.
Median PFS was 3.0 months (95% CI 1.7–7.3 months), and 6-
and 12-month PFS rates were 31.6% and 19.7%, respectively (sup
plementary Figure S1A, available at Annals of Oncology online).
Median OS was 9.3 months (95% CI, 5.9 months to not avail-
able), and the 6- and 12-month OS rates were 64.5% and 47.6%,
respectively (supplementary Figure S1B, available at Annals of
Oncology online).
Discussion
Because PD-L1 expression is associated with higher antitumor
activity of PD-1 blockade in other tumor types [12–14], PD-L1
positivity was used as a selection criterion in this study to poten-
tially enrich for patients most likely to respond to pembrolizu-
mab. In this population of mostly pretreated patients with
PD-L1-positive advanced anal carcinoma, pembrolizumab dem-
onstrated manageable safety and encouraging antitumor activity,
with an ORR of 17% in those patients with SCC histology (4 of 24
patients). To our knowledge, this study represents the first pub-
lished manuscript describing immune checkpoint blockade in
patients with previously treated advanced anal carcinoma.
PD-L1 positivity, which had not been previously defined in
anal cancer, was found to be high (74% of screened patients) in
this study. The high rate of PD-L1 expression in anal cancer may
not be surprising given the immune responses against the HPV
E7 oncoprotein identified previously in this tumor type [16].
High frequencies of tumor-infiltrating lymphocytes and inflam-
matory responses have been identified in virally driven cancers
and have been linked with upregulation of PD-L1 in HPV-
associated head and neck cancer [17–19]. This upregulation of
PD-L1 is mediated by interferon-c secreted by T cells and has
been termed ‘adaptive immune resistance’ [8, 20]. HPV status
was not collected in this study and was only available for three of
the enrolled patients (two responders and one non-responder),
all of whom were HPV positive. The number of patients in this
study with known HPV status was too small to determine an as-
sociation with pembrolizumab activity.
Similar to the results of other immune checkpoint inhibitors
in various tumor types [11–13], only a subset of patients with PD-
L1-positive tumors in this study experienced clinical benefit, sug-
gesting that other biomarkers should be explored for the ability to
predict antitumor activity of pembrolizumab. Immune gene signa-
tures were shown to correlate with response to PD-1 blockade in sev-
eral other solid tumor types [21–23], and an association between
tumor infiltration of CD8þ and CD3þT cells with response to PD-
1 inhibition was reported with another anti-PD-1 antibody, nivolu-
mab, in patients with SCC anal carcinoma [24]. Mutational load has
been reported to correlate with response to immune checkpoint
blockade in other cancers including melanoma, non-small cell lung
cancer, and colorectal cancer, and may be relevant in advanced anal
carcinoma as well [25–28]. Although the mutational rate of anal can-
cer has not been assessed comprehensively, it has been reported to
be in the intermediate range, along with other HPV-associated can-
cers such as head and neck and cervical cancer [29–31].
In conclusion, pembrolizumab demonstrated manageable
safety and encouraging antitumor activity in patients with PD-
L1-positive advanced SCC anal carcinoma. Further evaluation of
PD-1 blockade, alone or in combination with a partnering agent,
in this patient population and of potential biomarkers is
warranted.
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